BioSciences

Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates

WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020

Clinical Utility of WAKIX was Expanded with Additional Approval for Treatment of Cataplexy in Adults with Narcolepsy

Enrollment Continues in Phase 2 Trial of Patients with Prader-Willi Syndrome

On Track to Initiate Two Additional Clinical Trials with Pitolisant in 2021

Conference Call and Webcast to be Held Today at 8:30 a.m. ET

PLYMOUTH MEETING, Pa., March 25, 2021 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly

Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected
by mid-year 2021

Interim data releases expected from PBCAR269A and PBCAR20A in 2021

Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell,
anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma; Phase 1 study expected to be initiated by mid-year 2021

DURHAM, N.C., March 18, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today